drugset / Trial / NCT06042647
Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis
Non-randomizedSingle-groupSingle-blindTreatment
Summary
The objective of this research is to demonstrate superior anti-inflammatory effects, as demonstrated by a reduction in TNF-a and IL-17A, with tazarotene/halobetasol lotion in patients with mild to moderate plaque type psoriasis as compared to clobetasol propionate 0.05% cream.
Timeline
- Start
- 2023-07-13
- Primary completion
- 2023-11-13
- Completion
- 2023-11-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Halobetasol | Unknown | 0.01 % | Topical |
| Comparator | Tazarotene | Small molecule | 0.045 % | Topical |
| Comparator | clobetasol propionate | Small molecule | 0.05 % | Topical |